SCHEMBL258343

SCHEMBL258343

CCCCCC=CCC=CCCCCCCCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 1.00
PPARD Q03181 6/20 1.00
PPARA Q07869 6/20 1.00
ALDH1A1 P00352 5/20 1.00
F7 P08709 5/20 1.00
F3 P13726 5/20 1.00
FABP4 P15090 4/20 1.00
HSD17B10 Q99714 4/20 1.00
FFAR1 O14842 3/20 1.00
PTGS1 P23219 3/20 1.00
LMNA P02545 3/20 1.00
CYP19A1 P11511 3/20 1.00
ALOX15 P16050 3/20 1.00
NR4A2 P43354 3/20 1.00
KDM4E B2RXH2 2/20 1.00
CYP3A4 P08684 2/20 1.00
HPGD P15428 2/20 1.00
AKR1C3 P42330 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
DUSP3 P51452 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16685715 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
SCHEMBL15880317 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
Linoleic Acid SCHEMBL20856202 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
SCHEMBL22498259 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
SCHEMBL22498256 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
Arachidic Acid SCHEMBL20528087 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
Linoleic Acid SCHEMBL25294178 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
SCHEMBL22498258 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
Dihomo-Gamma-Linolenic Acid SCHEMBL20656585 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7
SCHEMBL21411004 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1F7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024108603-A1 FECAL METABOLITE-BASED NEURODEGENERATIVE DISEASE MARKER, AND USE THEREOF 中国科学院深圳先进技术研究院 2024-05-30 WO claimed
CN-118090931-A Neurodegenerative disease marker based on fecal metabolites and application thereof 中国科学院深圳先进技术研究院 2024-05-28 CN claimed
US-20100069491-A1 LIPID-AMINO ACID CONJUGATES AND METHODS OF USE UNIVERSITY OF MASSACHUSETTS (US) 2010-03-18 US claimed
US-7544714-B2 Lipid-amino acid conjugates and methods of use UNIVERSITY OF MASSACHUSETTS (US) 2009-06-09 US claimed
EP-1778210-A2 LIPID-AMINO ACID CONJUGATES AND METHODS OF USE University of Massachusetts (US) 2007-05-02 EP claimed
WO-2006010153-A2 LIPID-AMINO ACID CONJUGATES AND METHODS OF USE UNIVERSITY OF MASSACHUSETTS (US) 2006-01-26 WO claimed
US-20060014820-A1 Lipid-amino acid conjugates and methods of use NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-01-19 US claimed
US-20260146254-A1 Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications SEGENA CORPORATION S.A. (UY) 2026-05-28 US disclosed
EP-4622674-A1 ENHANCING OLIGONUCLEOTIDE IMMUNOMODULATORY ACTIVITY THROUGH DIANOPHORE LONG-LASTING MODIFICATION: METHODS AND APPLICATIONS SEGENA CORPORATION S.A. (UY) 2025-10-01 EP disclosed
US-20250143359-A1 COMPOUNDS THAT MODULATE GPR92 RECEPTOR ACTIVITY AND PET FOOD PRODUCTS CONTAINING THE SAME MARS, INCORPORATED (US) 2025-05-08 US disclosed
EP-4150103-B1 METHOD FOR MANUFACTURING HYDROXY FATTY ACID-BASED POLYOLS U WINDMOELLER INNOVATION GMBH & CO KG (DE) 2025-04-09 EP disclosed
WO-2023213310-A9 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2025-02-20 WO disclosed
US-12207672-B2 Compounds that modulate GPR92 receptor activity and pet food products containing the same MARS, INCORPORATED (US) 2025-01-28 US disclosed
EP-1188440-A1 MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2002-03-20 EP disclosed
EP-0827401-A2 METHODS AND COMPOSITIONS FOR INHIBITING ALPHA-REDUCTASE ACTIVITY ARCH DEVELOPMENT CORPORATION (US) 1998-03-11 EP disclosed
US-5605929-A REDUCING WEIGHT IN ANIMALS ARCH DEVELOPMENT CORP. (US) 1997-02-25 US disclosed
WO-1996037201-A2 METHODS AND COMPOSITIONS FOR INHIBITING 5α-REDUCTASE ACTIVITY ARCH DEVELOPMENT CORPORATION (US) 1996-11-28 WO disclosed
EP-0132346-B1 NOVEL COMPOUNDS AND COMPOSITIONS USEFUL FOR PRODUCING ANALGESIA THE PROCTER & GAMBLE COMPANY (US) 1986-09-24 EP disclosed
US-4544669-A ALKADIENAMIDES THE PROCTER & GAMBLE COMPANY (US) 1985-10-01 US disclosed
EP-0132346-A1 Novel compounds and compositions useful for producing analgesia THE PROCTER & GAMBLE COMPANY (US) 1985-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014820-A1 Lipid-amino acid conjugates and methods of use SLC27A2, SLC27A1, FABP2 PPARG 160/4885PPARD 447/4885PPARA 224/4885
US-20100069491-A1 LIPID-AMINO ACID CONJUGATES AND METHODS OF USE SLC27A2, SLC27A1, FABP2 PPARG 160/4885PPARD 447/4885PPARA 224/4885
US-20260146254-A1 Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications CD44, ADAR, TLR9 PPARG 1357/4885PPARD 2310/4885PPARA 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.